atopic dermatitis

warning sign
Biotech

New cancer cases prompt Kyowa to shutter rocatinlimab trials

Kyowa had originally planned to seek FDA approval of the asset in atopic dermatitis in the first half of this year.
Gabrielle Masson Mar 3, 2026 11:00am
Close up shot of the target from a dart game

Lynk sees ph. 3 eczema win as proof of JAK inhibitor's potential

Mar 2, 2026 8:55am
Completing steps towards success checkmark on cubes symbolizing progress

Nektar eczema asset 'checked all of the boxes' in phase 2

Feb 10, 2026 10:55am
Graphic image of an arrow nailing the bullseye of a target

Evommune's Dupixent-like eczema data drive 75% stock rally

Feb 10, 2026 9:31am
Return To Sender stamp on an envelope

Amgen exits $400M autoimmune pact after running vast program

Jan 30, 2026 8:55am
success failure signposts

Sanofi posts mixed phase 3 data on key eczema prospect

Jan 23, 2026 5:43am